Contents

Highlights of This Issue 3809

SPECIAL FEATURES

3811  New Strategies in Colorectal Cancer: Biomarkers of Response to Epidermal Growth Factor Receptor Monoclonal Antibodies and Potential Therapeutic Targets in Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Pathways
Arvind Dasari and Wells A. Messersmith

3819  Killing the Killer: Natural Killer Cells to Treat Ewing’s Sarcoma
Yong-Oon Ahn, Brenda Weigel, and Michael R. Verneris
See article p. 3901

3822  Fluorescence Resonance Energy Transfer Biosensors for Cancer Detection and Evaluation of Drug Efficacy
Shaoying Lu and Yingxiao Wang
See article p. 3964

Molecular Pathways

3825  Deregulated Intracellular Signaling by Mutated c-CBL in Myeloid Neoplasms
Seishi Ogawa, Lee-Yung Shih, Takahiro Suzuki, Makoto Otsu, Hiromitsu Nakauchi, H. Phillip Koeffler, and Masashi Sanada

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

3832  Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk
Zhe-Yi Hu, Qi Yu, Qi Pei, and Cheng Guo

HUMAN CANCER BIOLOGY

3843  Sperm DNA Integrity in Men Treated for Childhood Cancer
Patrik Romerius, Olof Ståhl, Christian Möll, Thomas Relander, Eva Cavallin-Ståhl, Helen Gustafsson, Kerstin Löfqvander Thapper, Katarina Jepson, Marcello Spanò, Thomas Wiebe, Yvonne Lundberg Giwercman, and Aleksander Giwercman

3851  GDF-15 Contributes to Proliferation and Immune Escape of Malignant Gliomas
Patrick Roth, Markus Junker, Isabel Tritschler, Michel Mittelbronn, Yvonne Dombrowski, Samuel N. Breit, Ghazaleh Tabatabai, Wolfgang Wick, Michael Weller, and Jörg Wischhusen

3860  Clinical Implications of Gene Dosage and Gene Expression Patterns in Diploid Breast Carcinoma
Toshima Z. Parris, Anna Danielsson, Szilárd Nemes, Anikó Kovács, Ulla Delle, Ghita Fallenius, Elin Möllerström, Per Karlsson, and Khalil Helou

3875  CXCR2 Promotes Ovarian Cancer Growth through Dysregulated Cell Cycle, Diminished Apoptosis, and Enhanced Angiogenesis
Gong Yang, Daniel G. Rosen, Guangzhi Liu, Fan Yang, Xiaojing Guo, Xue Xiao, Fengxia Xue, Imelda Mercado-Uribe, Jiaoti Huang, Sue-Hwa Lin, Gordon B. Mills, and Jingsong Liu

CANCER THERAPY: PRECLINICAL

3887  Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy
Anil Bagri, Leanne Berry, Bert Gunter, Mallika Singh, Ian Kasman, Lisa A. Damico, Hong Xiang, Maike Schmidt, Germaine Fuh, Beth Hollister, Oliver Rosen, and Greg D. Plowman
Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors
Duck Cho, David R. Shook, Noriko Shimasaki, Yu-Hsiang Chang, Hiroyuki Fujisaki, and Dario Campana
See commentary p. 3819

Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles
Hee Dong Han, Lingegowda S. Mangala, Jeong Won Lee, Mian M.K. Shahzad, Hye Sun Kim, Deyu Shen, Eun Ji Nam, Edna M. Mora, Rebecca L. Stone, Chunhua Lu, Sun Joo Lee, Ju Won Roh, Alpa M. Nick, Gabriel Lopez-Berestein, and Anil K. Sood

The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy
Yue Wei, Tapan Kadia, Weigang Tong, Ming Zhang, Yu Jia, Hui Yang, Yumin Hu, Francesco Paolo Tambaro, Jean Viallet, Susan O’Brien, and Guillermo García-Manero

Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors
Andrea Bertotti, Cecilia Bracco, Flavia Girolami, Davide Torti, Stefania Gastaldi, Francesco Galimi, Enzo Medico, Paul Elvin, Paolo M. Comoglio, and Livio Trusolino

Metabolic Approach to the Enhancement of Antitumor Effect of Chemotherapy: a Key Role of Acetyl-l-Carnitine
Claudio Pisano, Loredana Vesci, Ferdinando Maria Milazzo, Mario Berardino Guglielmi, Rosanna Foderà, Marcella Barbarino, Maurizio D’Incalci, Massimo Zuccetti, Giovanna Petrangolini, Monica Tortoreto, Paola Pergo, Valentina Zucchi, Augusto Orlandi, Daniela Passeri, Paolo Carminati, Claudio Cavazza, and Franco Zunino

Epithelial Membrane Protein-2 Is a Novel Therapeutic Target in Ovarian Cancer
Maoyong Fu, Erin L. Mares, Robert A. Soslow, Mohammad Alavi, Wei Mah, Qin Zhou, Alexia Iasonos, Lee Goodglick, Lynn K. Gordon, Jonathan Braun, and Madhuri Wadehra

A Novel FRET-Based Biosensor for the Measurement of BCR-ABL Activity and Its Response to Drugs in Living Cells
Tatsuki Mizutani, Takeshi Kondo, Stephanie Darmanin, Masumi Tsuda, Shinya Tanaka, Minoru Tobiume, Masahiro Asaka, and Yusuke Ohba

Genetically Abnormal Circulating Cells in Lung Cancer Patients: An Antigen-Independent Fluorescence In situ Hybridization–Based Case-Control Study

BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy
Charles Dumontet, Maryla Krajewska, Isabelle Treilleux, John R. Mackey, Miguel Martin, Mathieu Rupin, Laurence Lafanèche, and John C. Reed

Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients
Pier Luigi Zinzani, Giuseppe Rossi, Silvia Franceschetti, Barbara Botti, Alice Di Rocco, Maria Giuseppina Cabras, Maria Concetta Petti, Vittorio Stefoni, Alessandro Broccoli, Stefano Fanti, Cinzia Pellegrini, Gian Carlo Montini, Letizia Gandolfi, Enrico Derenzini, Lisa Argnani, Mariapaola Fina, Alessandra Tucci, Chiara Bottelli, Stefano Pileri, and Michele Baccarani

CANCER THERAPY: CLINICAL
ABOUT THE COVER

CXC chemokine receptor 2 (CXCR2) expression in an ovarian cancer cell line detected by the immunofluorescent staining. Overexpression of CXCR2 in ovarian cancer cells leads to dysregulation of cell cycle, decreased apoptosis, and increased angiogenesis. The high level expression of CXCR2 also predicts poor prognosis in patients with high-grade ovarian serous carcinoma. For further details, please see the article by Yang and colleagues on page 3875 of this issue.